Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early‐stage lung adenocarcinoma

• DOI: 10.1111/his.14894
• Publication Date: 2023-02-28T03:14:50Z
• Authors: Tae H Hong; Soohyun Hwang; Yoon‐La Choi; Genehee Lee; Sehhoon Park; Myung‐Ju Ahn; Yoonseo Lee; Yeong J Jeon; Junghee Lee; Sumin Shin; Seong Y Park; Jong H Cho; Yong S Choi; Jhingook Kim; Young M Shim; Juhee Cho; Hong K Kim
• Keywords: 0301 basic medicine; Lung Neoplasms; Adenocarcinoma of Lung; Adenocarcinoma; Prognosis; ErbB Receptors; 03 medical and health sciences; 0302 clinical medicine; Mutation; Humans; Neoplasm Staging; Retrospective Studies

The prognostic role of EGFR mutations remains controversial. We aimed to evaluate the mutation in consideration IASLC histological grade patients with resected early-stage lung adenocarcinoma.A total 3297 stages I-IIA adenocarcinoma who had tests between January 2014 and December 2019 at Samsung Medical Center, Seoul, Korea were included. Recurrence-free survival (RFS) was compared by status (EGFR-M+ versus EGFR-WT) (G1, G2 G3). Cox proportional hazards models used estimate adjusted HRs (aHRs) 95% confidence intervals (CIs).Compared EGFR-WT group, EGFR-M+ group a significantly lower proportion G3 tumour (16 33%, P < 0.001). During median follow-up 41.4 months, 376 experienced recurrence. After adjusting for grade, aHR recurrence comparing 1.30 (95% CI = 1.04-1.62, 0.022). 5-year RFS than among (58.4 71.5%, 0.001), but not G1 patients.EGFR associated risk after grading, especially tumours. results this study would be useful developing new staging system identifying subset may benefit from adjuvant targeted therapy.